CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
Described herein are crystalline forms of Compound 1 useful for the prevention and treatment of angiogenic ocular conditions; methods of treating a disease comprising; processes for preparing; and kits comprising, the same.
1 . A crystalline form of Compound 1:
wherein the crystalline form has an X-ray powder diffraction (XRPD) pattern with a largest peak at about 8-9 degrees 2θ.
2 . The compound of claim 1 wherein the crystalline form is an anhydrate.
3 . A process for preparing a crystalline form of either of claim 1 or claim 2 , comprising mixing Compound 1 and ethyl acetate.
4 . A pharmaceutical composition comprising the crystalline form of either of claim 1 or claim 2 and a pharmaceutically acceptable carrier.
5 . The pharmaceutical composition of claim 4 , wherein the pharmaceutical composition is suitable for topical administration.
6 . The pharmaceutical composition of claim 4 , wherein the pharmaceutical composition is suitable for injection.
7 . The pharmaceutical composition of any one of claims 4 , 5 or 6 , wherein the pharmaceutical composition is suitable for delivery to the eye.
8 . A kit comprising the crystalline form of any one of claims 1 , 2 , or 3 , or the pharmaceutical composition of any one of claims 4 , 5 , 6 , or 7 .
9 . A method of treating a disease comprising administering to a subject in need thereof a therapeutically effective amount of the crystalline form of any one of claims 1 or 2 or the pharmaceutical composition of any one of claims 4 , 5 , 6 , or 7 .
10 . The method of claim 9 , wherein the disease is a proliferative disease.
11 . The method of claim 8 , wherein the disease is cancer.
12 . The method of claim 9 , wherein the disease is an ocular disease.
13 . The method of claim 9 , wherein the disease is retinopathy.
14 . The method of claim 9 , wherein the disease is age-related macular degeneration (AMD).
15 . The method of claim 9 , wherein the disease is corneal neovascularization.
16 . A method of inhibiting growth factor signaling comprising administering to a subject a therapeutically effective amount of the crystalline form of any one of claims 1 or 2 or the pharmaceutical composition of any one of claims 4 , 5 , 6 , or 7 .